← GIP/GLP-1 & amylin agonists × glycemic control

TrialDiabetes, obesity & metabolism2024

5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.

Shu Niu et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2024

Not counted

Probably lowered glycemic control

−36%−39% to −33%

Bigger than 3 in 10 for glycemic control

As reported

IRR 0.64, 95% CI 0.61–0.67

Not counted

Probably lowered glycemic control

−33%−36% to −30%

Bigger than 3 in 10 for glycemic control

As reported

RR 0.67, 95% CI 0.64–0.70

Not counted

Probably lowered glycemic control

−25%−28% to −21%

Bigger than 2 in 10 for glycemic control

As reported

RR 0.75, 95% CI 0.72–0.79

Not counted

Probably lowered glycemic control

−21%−24% to −18%

Bigger than 2 in 10 for glycemic control

As reported

RR 0.79, 95% CI 0.76–0.82

Four numbers in the abstract

the abstract, start to end

… adverse events [rate ratio (RR) 0.64, 95% confidence interval (CI) 0.61-0.67] and microvascular composite (RR 0.67, 95% CI 0.64-0.70) with 15 mg tirzepatide, and 5-year risk reduction in cardiovascular adverse events (RR 0.75, 95% CI 0.72-0.79) and microvascular composite …

← favours treatmentfavours comparator →
could be chance
Glycemic control
IRR 0.640.61–0.67
Glycemic control
RR 0.670.64–0.70
Glycemic control
RR 0.750.72–0.79
Glycemic control
RR 0.790.76–0.82
GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsInsulinGlycemic control
1 / 3

6 papers cite it

2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 37867175